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Background: Lower extremity (LE) peripheral artery disease (PAD), which is associated with a reduced quality of life
and increased mortality from atherosclerotic cardio-/cerebro-vascular occlusion, is a significant public health problem,
especial for an aging society such as that of Taiwan.
Methods: Specific datasets of the 2000–2011 nationwide inpatient databases were analyzed. Two inclusion criteria,
including one of the major diagnosis codes of PAD and one of three categorical invasive treatments of LE PAD, were
used consecutively to select cases diagnosed as LE PAD and receiving invasive treatment. The epidemiology of
invasively-treated PAD in Taiwan was estimated, and the influences of potential confounders on these
invasively-treated methods were evaluated.
Results: In general, the invasively-treated incidence of PAD in Taiwan doubled, from 3.73/10,000 (in 2000) to
7.48/10,000 (in 2011). On average, the total direct medical cost of one hospitalized and invasively-treated PAD
case ranged from $US 4,600 to $US 5,900. The annual cases of bypass surgery for the PAD cases averaged 1,000 and
the cases for limb amputation ranged from 4,100 to 5,100 annually. However, the number of percutaneous transluminal
angioplasty (PTA) procedures remarkably increased by 15 times, from 600/year to 9,100/year, from 2000 to 2011. 51.3%
of all the enrolled cases were treated with limb amputations, and female, young and middle-aged people (30–65 years
of age), DM patients and those on a low income had a tendency to undergo amputation due to PAD. 37.6% of all the
enrolled cases were treated with PTAs related to hypertension, cardiovascular disease, hyperlipidemia and catastrophic
Illness. 2-year PTA failure rates of 22.13%, 11.91% and 10.61% were noted among the first (2000–2001), second
(2004–2005) and the third (2008–2009) cohort groups, respectively.
Conclusions: In Taiwan, a gender difference and age and period effects on the invasively-treated incidence of LE
PAD were observed. Female, young and middle-aged people (30–50 and 50–65 years of age), DM patients and
those on a low income had a tendency to undergo amputation. The number of PTA procedures remarkably
increased, but the 2-year failure rate of PTAs reduced from 2000 to 2011.
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Peripheral artery disease (PAD) is a common condition
used to describe the impairment of blood flow, especially
to the lower extremities, that is usually a result of ath-
erosclerotic occlusion. PAD occurrence has been noted to
increase dramatically with age, and black race/ethnicity,
current smoking, diabetes, hypertension, hypercholes-
terolemia, and low kidney function were found to be
positively associated with prevalent PAD [1]. Otherwise,
a family history of PAD is independently strongly asso-
ciated with PAD prevalence and severity. This indicates
a role of genetic factors or other shared environmental
factors, or both, contributing to PAD [2].
Lower extremity (LE) PAD with clinical symptoms
causes a significant reduction in quality of life [3]. More
importantly, it is a marker of atherosclerotic disease
burden, and is associated with increased mortality from
cardiovascular and cerebrovascular causes [4]. A meta-
analysis study including sixteen population cohort studies
(a total of 480,325 person-years of follow-up of 24,955
men and 23,339 women) concluded that a low ankle-
brachial index (ABI) (< or = 0.90) was associated with
approximately twice the 10-year total mortality, cardio-
vascular mortality, and major coronary event rates as
compared with the overall rate in each Framingham risk
score (FRS) category [5].
However, approximately 40%-50% of patients with PAD
are asymptomatic [4,6]; therefore, it is difficult to estimate
its true prevalence in a community. Under-diagnosis
and under-treatment of PAD are predicted in many
countries. In patients with PAD, antiplatelet drugs and
statins, exercise rehabilitation programs, lower extremity
angioplasty, or bypass surgery are the current manage-
ment strategies, and limb amputation is a critical method
to save patients’ lives [7].
Therefore, PAD is a significant public health problem,
especial for an aging society such as that of Taiwan. From
the viewpoint of epidemiology of nationwide medical
utilization, the present study aimed (1) to estimate the
hospitalized incidence of PAD patients in Taiwan who
were admitted to receive invasive treatments, and (2) to
analyze the possible factors related to the different inva-
sive treatment methods.
Methods
Source, security, and quality control of data
Taiwan launched a single-payer National Health Insur-
ance (NHI) Program on March 1, 1995. As of 2011,
23.199 million of Taiwan’s total population of 23.225
million were enrolled in this program; foreigners in
Taiwan are also eligible for inclusion. All enrollees enjoy
almost free access to healthcare with a small co-payment
by most clinics and hospitals [8]. This universal national
health insurance, financed jointly by payroll taxes, subsidies,and individual premiums, commenced in Taiwan, and
its coverage expanded from 57% of the population
(before the introduction of national health insurance)
to more than 98% (after the year 2005), and then to
99% (after the year 2007). The NHI has consistently
received a 70 percent public satisfaction rate [9]. In order
to respond to current and emerging health issues rapidly
and effectively, the National Health Research Institute
(NHRI), in cooperation with the National Health Insur-
ance Bureau (NHIB), established a nationwide research
database. The NHIB has established a uniform system
to control the quality of medical services and coding.
The NHRI safeguards the privacy and confidentiality of
those included in the database and routinely transfers
health insurance data from the NHIB to enable health
researchers to analyze and improve the health of Taiwan’s
citizens. The NHI database contains registration files
and original claims data for reimbursement, and access
to the National Health Insurance Research Database
(NHIRD), which was derived from this system by the
NHIB and is maintained by the NHRI, is provided to
scientists in Taiwan for research purposes [10-13].
Data protection and permission
Data in the NHIRD that could be used to identify
patients or care providers, including medical institu-
tions and physicians, are scrambled before being sent
to the NHRI for database inclusion, and are further
scrambled before being released to each researcher.
Theoretically, it is impossible to query the data alone
to identify individuals at any level using this database. All
researchers who wish to use the NHIRD and its data
subsets are required to sign a written agreement declar-
ing that they have no intention of attempting to obtain
information that could potentially violate the privacy of
patients or care providers. This study protocol was eval-
uated by the NHRI, who gave their agreement to the
planned analysis of the NHIRD (Agreement Number:
NHIRD-101-566). This study was also approved by the
Institutional Review Board (IRB) of Taoyuan General
Hospital, which has been certificated by the Department
of Health, Taiwan (IRB Approval Number: TYGH101049).
Data selection and definitions of PAD, its related
treatments and other co-morbidities
Specific datasets of the NHI research database, including
“monthly claims summary for inpatient claims”, “inpatient
cost by admission” and “details of inpatient orders” from
between 2000 and 2011 were analyzed. In order to investi-
gate the invasively-treated incidence of PAD, the Inter-
national Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) diagnosis codes and ICD-9-CM
treatment codes were evaluated. Two inclusion criteria
were used consecutively to select cases that were
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treatment methods for LE PAD. The major diagnosis
codes of PAD and three categorical invasive treatments
of LE PAD were defined as shown in Table 1. Otherwise,
the potential risk factors of invasive treatments and
patients’ demographic information, socioeconomic charac-
teristics, and pre-existing diseases, cardiovascular disease,
diabetes mellitus, end-stage renal disease (ESRD), hyperlip-
idemia, and severity of co-morbidities were included.
If a patient’s ailment is diagnosed by a physician as a
“catastrophic illness” under Department of Health guide-
lines, the patient can submit related information and
apply for a catastrophic illness certificate. The applica-
tion will be formally reviewed, and if approved, the
information is entered into his or her IC card. In the
present study, the 2000–2011 catastrophic illness reg-
istered dataset of Taiwan (including 30 categories) [13]
was used to verify the Catastrophic-Illness-Registration
(CIR) cases from the sampled population.Table 1 ICD-9-CM definitions of PAD and related treatments
Diagnoses or Treatments
Diagnoses: PAD
Treatments: PTA series (Percutaneous Transluminal Angioplasty)
Treatments: Bypass surgery
Treatments: AmputationIn addition, the Charlson comorbidity index (CCI), de-
veloped by Charlson and colleagues [14], was calculated
to indicate the severity of co-morbidities based on pa-
tients’ medical diagnosis codes (ICD-9-CM).
Statistics
We compared baseline characteristics by descriptive sta-
tistics, represented by the numbers of cases, percentages,
and means with standard deviation (SD), and cumulative
incidence (Inc). The influence of potential confounders on
the invasive treatment methods of percutaneous translu-
minal angioplasty (PTA), bypass surgery and amputation
were calculated by Pearson’s chi-square (χ2) test and odds
ratios (ORs) with 95% confidence intervals (95% CIs). Sig-
nificance was set at p = 0.05. Further multivariate analysis
by Poisson regression was performed to evaluate the
period effect of PTA failure and other potential con-
founders on the risk of amputation or bypass, as shown
by the risk ratio (RR) with the 95% confidence intervalRange of ICD-9-CM codes
440.0 (atherosclerosis of aorta)
440.2 (atherosclerosis of native arteries of the extremities),
440.3 (atherosclerosis of bypass graft of the extremities),
440.8 (atherosclerosis of other specific arteries)
440.9 (other atherosclerosis of native arteries of the extremities)
443 (other peripheral vascular disease)
444.0 (arterial embolism, thrombosis of abdominal aorta)
444.22 (arterial embolism & thrombosis of lower extremity)
444.8 (arterial embolism, thrombosis of other specific artery)
444.9 (embolism & thrombosis of unspecific artery)
447.8 (other specific disorders of arteries and arterioles)
447.9 (unspecific disorders of arteries and arterioles)
38.08 (incision of vessel, lower limb arteries)
38.18 (endarterectomy, lower limb arteries)
38.38 (resection of vessel with anastomosis, lower limb arteries)
38.48 (resection of vessel with replacement, lower limb arteries)
38.68 (other excision of vessel, lower limb arteries)
38.88 (other surgical occlusion of vessel, lower limb arteries)
39.50 (angioplasty or atherectomy of non-coronary vessel)
39.7 (Endovascular repair of vessel)
39.90 (insertion of non-coronary artery stent)
39.25 (aorta-iliac-femoral bypass)
39.26 (other intra-abdominal vascular shunt or bypass)
39.29 (other(peripheral) vascular shunt or bypass)
84.1 (amputation of lower limb)
84.10 ~ 84.15 low level amputation (amputation below knee)
84.16 ~ 84.19 high level amputation (knee disarticulation or above)
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the Statistical Package for Social Sciences for Windows
(SPSS for Windows 19.0).
Results
Table 2 shows the annual enrolled subjects hospitalized
in order to receive one of the invasive treatments for
PAD. The invasively-treated incidence of PAD could be
estimated classified by gender and age stratum. In general,
the invasively-treated incidence of PAD in Taiwan dou-
bled, from 3.73/10,000 (in 2000) to 7.48/10,000 (in 2011).
There was an obvious increasing trend of the treated inci-
dence of PAD by age stratum. Male patients were more
likely to suffer from PAD with invasive treatment needed,
and the incidence ratio (IR) of male vs female increased
from 1.34 (in 2000, the estimated incidences of the male
and female patients being 4.27 and 3.18 per 10,000, re-
spectively) to 1.57 (in 2011, the estimated incidences of
the male and female patients being 9.17 and 5.83 per
10,000, respectively). The nationwide and averaged indi-
vidual medical costs are shown in Figure 1. On average,
the total direct medical cost of one hospitalized and
invasively-treated PAD case ranged from $US 4,600 to
$US 5,900, and the treatment fee accounted for 14.8-
18.2% of the total medical cost. Along with the increase
in enrolled case numbers annually, the national total
medical expenditure for these invasively-treated PAD cases
increased greatly from $US 15.5 million per year (in 2000)
to $US 59.6 million per year (in 2011) in Taiwan.
Figure 2 shows the annual distributions of various
invasive treatment methods for hospitalized PAD cases
in Taiwan from 2000 to 2011. The invasive treatmentTable 2 Hospitalized Incidence* of PAD patients receiving an







Male Female 30-49.9 yea
Inc. Inc. Inc.
2000 4,446 11,917,551 3.731 4.27 3.18 0.46
2001 4,364 12,154,222 3.591 4.06 3.11 0.45
2002 4,610 12,379,716 3.724 4.28 3.16 0.49
2003 4,778 12,598,220 3.793 4.31 3.25 0.47
2004 6,339 12,822,685 4.944 5.76 4.12 0.62
2005 7,017 13,054,059 5.375 6.40 4.35 0.73
2006 6,773 13,362,944 5.068 6.07 4.07 0.61
2007 7,065 13,614,777 5.189 6.29 4.10 0.68
2008 7,975 13,889,004 5.741 7.11 4.81 0.74
2009 8,437 14,182,660 5.989 7.23 4.70 0.79
2010 9,369 14,456,222 6.481 7.84 5.16 0.83
2011 11,013 14,728,045 7.478 9.17 5.83 1.00
*Incidence (Inc.): 1/10,000
Note: a: This was data-mined from the nationwide health insurance inpatient datab
codes and ICD-9-CM treatment codes for PAD simultaneously. b: This was selected f
as (a/b) × 10,000.methods mainly included PTAs, bypass operations or
limb amputations. The annual cases of bypass surgery
for the PAD cases averaged 1,000, but the treatment
incidence among subjects aged 30 years or more was
estimated as 8.4 per 100,000, and reduced to 6.4 per
100,000 from 2000 to 2011. The number of limb am-
putations varied annually, and ranged from 4,100 to
5,100 during the 12-year study period. However, the
amount of PTA procedures remarkably increased by
15 times, from 600/year to 9,100/year from 2000 to
2011. At the same time, the number of hospitals with the
ability to perform PTAs doubled from 2000 to 2011. To
investigate the possible factors affecting the various in-
vasive treatments for PAD in Taiwan, all three main
methods to treat PAD invasively were summed from
2000 to 2001. Table 3 shows the age, gender, co-morbidity
and socio-economic status effects on the performance of
different invasive treatment methods for the hospitalized
PAD cases in Taiwan. In total, 51.3% of the enrolled cases
were treated with limb amputation, and female, young
and middle-aged people (30–50 and 50–65 years of age),
DM patients and those on a low income had a tendency
to undergo amputation due to PAD (significant odds ra-
tios (ORs): 1.12, 1.30, 11.22, 6.12 and 1.41, respectively).
In total, 37.6% of the enrolled cases were treated with
PTAs; hypertension, cardiovascular disease, and hyper-
lipidemia patients, and people with Catastrophic Illness
Registration (CIR) were at greater risk of receiving a
PTA procedure for PAD (significant OR: 3.11, 3.45,
7.20 and 1.81, respectively). Only ESRD patients were
more likely to receive a vascular surgery (significant
OR: 1.36).y invasive treatment among residents aged 30 years or














ank and the cases must meet the inclusion criteria of ICD-9-CM diagnostic
rom the year book of the nationwide population registry; c: This was calculated
Figure 1 Annual national hospitalization costs and averaged individual hospitalization costs of admitted PAD cases in Taiwan from
2000 to 2011.
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and hospitals with the ability to perform PTAs during
different periods (2000–2003 and 2004–2011) in Taiwan
was found when comparing Figure 2 and Figure 3.
Therefore, the outcome of these dominantly increased
PTA cases is worthy of evaluation. Three cohort sub-
groups (2000–2001 cohort, 2004–2005 cohort and 2008–
2009 cohort) were selected in order to evaluate their
middle-term (two years) results after PTA treatment
(Table 4). To calculate the failure rate of PTAs, all cases
referred for another bypass surgery or amputation pro-
cedure were recorded, and there were 22.13% (7.27%Figure 2 Annual distributions of various invasive treatment methods fo
treatment methods mainly included PTAs, bypass operations or limb amputareferred for a bypass; 14.86% referred for an amputation),
11.91% (3.75% and 8.16% referred for a bypass and ampu-
tation, respectively) and 10.61% (2.10% and 8.51% referred
for a bypass and amputation, respectively) failure rates
of original PTAs among the first (2000–2001), second
(2004–2005) and third (2008–2009) cohorts, respect-
ively. A declining period effect on PTA failure could be
identified. Poisson regression models were used to evalu-
ate the associated factors related to failed PTAs among
the three cohort groups. In the first cohort, aging was
the most dominant factor (significant relative risks (RR)
ranging from 3.5 to 5.0 compared with the 30–50 yearsr hospitalized PAD cases in Taiwan from 2000 to 2011. The invasive
tions.
Table 3 Summed various invasive treatment methods for hospitalized PAD cases and associated factors in Taiwan from
2000–2011
Total cases (%) 111,495 PTA
(n = 41,987, 37.6%)
Bypass
(n = 12,334, 11.1%)
Amputation





No. (%) No. (%) No. (%)
Gender
Male 60,187 (59.5%) 25,372 60.4 7,772 63.0 33,366 58.4 <0.001
Female 40,936 (40.5%) 16,615 39.6 4,562 37.0 23,808 41.6a 1.12a (1.09-1.14)
Age Stratum
30–49.9 y/o 7,063 (7.0%) 2,594 6.2 748 6.1 4,182 7.3a <0.001 1.30a (1. 24–1.37)
50–64.9 y/o 26,138 (25.8%) 10,405 24.8 2,704 21.9 15,317 26.8a 1. 22a (1.18-1.25)
65–74.9 y/o 31,070 (30.7%) 12,820 30.5 4,107 33.3b 17,537 30.7 1.03b (0.98-1.08)
> = 75y/o 36,866 (36.5%) 16,169 38.5 4,775 38.7 20,138 35.2
Diabetes
Yes 69,026 (68.2%) 20,282 48.3 6,978 56.6 48,318 84.5a <0.001 6.12a (5.95-6.31)
Hypertension
Yes 45,961 (45.4%) 25,844 61.5c 5,918 48.0 18,635 32.6 <0.001 3.11c (3.03-3.19)
ESRD
Yes 11,318 (11.2%) 4,094 9.7 1,741 14.1b 6,313 11.0 <0.001 1.36b (1.29-1.44)
CAD
Yes 16,072 (15.9%) 10,727 25.5c 2,254 18.3 4,635 8.1 <0.001 3.45c (3.33-3.58)
Dyslipidemia
Yes 4,803 (4.7%) 3,960 9.4c 438 3.6 690 1.2 <0.001 7.20c (6.68-7.77)
Group identified
Normal 72,520 (71.7%) 27,500 65.5 9,530 77.3 43,391 75.9 <0.001
Low-income 2,704 (2.7%) 875 2.1 249 2.0 1,831 3.2a 1.41a (1.30-1.53)
CIR 25,913 (25.6%) 13,620 32.4c 2,557 20.7 11,957 20.9 1.81c (1.76-1.87)
OR: odds ratio calculated by the Chi-square method; CI: Confidence Interval.
ESRD: end-stage renal disease; CAD: cardiovascular disease.
CIR: Catastrophic Illness Registration.
Note: a: This represents the odds ratio of amputation in this subgroup compared to the others. b: This represents the odds ratio of bypass surgery in this subgroup
compared to the others. c: This represents the odds ratio of PTAs in this subgroup compared to the others.
Figure 3 The annual numbers of hospitals with the ability to perform PTA procedures in Taiwan, 2000–2011.
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Table 4 Poisson regression model of PTA failurea in the PAD cases for various time periods in Taiwan
Cohort I: PTAs performed
during 2000-2001
Cohort II: PTAs performed
during 2004-2005
Cohort III: PTAs performed
during 2008-2009
Descriptive data for both failed patterns No. (%) No. (%) No. (%)
Enrolled cases 1,265 5,356 10,258
Referred for bypass within 2 years 92 7.27% 201 3.75% 215 2.10%
Referred for amputation within 2 years 188 14.86% 437 8.16% 873 8.51%
Period effectb of PTAs Failure (RR, 95% C.I.) 1.00 0.92 0.80-1.04 0.92 0.80-1.06
Analytic data for all PTA failed cases RR (95% CI) RR (95% CI) RR (95% CI)
Age Stratum
30-49.9 y/o 1.00 1.00 1.00
50-64.9 y/o 3.54 1.68 ~ 5.49 1.45 0.84 ~ 1.85 1.10 0.73 ~ 1.42
65-74.9 y/o 4.95 2.41 ~ 10.13 1.54 0.82 ~ 1.76 1.17 0.78 ~ 1.50
75 y/o or more 4.56 2.22 ~ 9.36 1.63 0.83 ~ 1.79 0.92 0.72 ~ 1.19
Gender
Male vs female 0.87 0.69 ~ 1.11 0.85 0.72-0.99 1.10 0.97 ~ 1.26
Co-morbidities (CCI Index)
Higher (≥4) vs lower 1.54 0.95 ~ 2.43 1.31 1.02 ~ 1.67 1.46 1.20 ~ 1.77
Socioeconomic level
Low-income vs other 1.22 0.39 ~ 3.82 1.39 0.74 ~ 2.59 0.58 0.34 ~ 0.99
RR: risk ratio.
Note: a: This means that all the patients needed to be treated with additive bypass surgery or amputation within 2 years after their PTA procedure.
b: Crude relative ratio of period effect is to compare with the PTAs failure rate in period I and to keep off age-period interaction.
Chang et al. BMC Public Health 2013, 13:1107 Page 7 of 10
http://www.biomedcentral.com/1471-2458/13/1107of age group); in the second cohort, the female gender
and higher co-morbidities were major factors (signifi-
cant RR: 1.2 and 1.3, respectively). Regarding the most
recent (third) cohort, there was an additive effect of co-
morbidities and a negative effect of low-income status
on the failure of original PTAs (significant RR: 1.5 and
0.6, respectively).
Discussion
PAD is common, and much research has been con-
ducted to identify possible risk factors for PAD [15-17],
evaluate appropriate diagnostic modalities for PAD [18],
and develop effective treatments for symptomatic PAD
[19,20]. LE PAD is a common vascular condition that
affects both quality of life and life expectancy, with an
increased risk of cardiovascular events. Choice of endo-
vascular or surgical intervention remains controversial
in an ever-evolving field, and tissue engineering is a de-
veloping area and aims to produce grafts with similar
patency [6]. The exact incidence or prevalence of LE
PAD is difficult to be evaluated due to different people,
different nations, and even different states of one coun-
try. For example, a multi-centers study at 350 primary
care practices of 25 cities in the United States, enrolling
a total of 6979 PAD patients, showed that among them,
the clinical presentation varies from no symptoms toatypical rest pain, intermittent claudication, ischemic
ulcers, or gangrene. Incidence of PAD throughout the
US was various from 10% to 29%, with or without
symptoms [21]. In Japanese patients with PAD, women
were found to have more severe symptomatic states
and uncontrolled risk factors, and the prevalence of
iliac artery lesions was lower, but below the knee lesions
were more severe in women [22]. Rapid progression of
PAD was found in hemodialysis Taiwanese patients, and
the prevalence of ABI <0.9 increased yearly (10.4%, 22.7%
and 27.9%, respectively; p < 0.001) [23]. Another retro-
spective study of a Singapore hospital discharge database
(2004–2009) noted that DM patients with renal disease
had significantly higher rates of lower extremity amputa-
tion (7.1%) compared to DM patients without renal dis-
ease (2.5%, p < 0.001) [24]. In the present study, gender,
various age strata and co-morbidity (including diabetes,
hypertension, ESRD, cardiovascular disease (CAD), hyper-
lipidemia and an integrated co-morbidity index) were
found to have significant effects on the performance of
different invasive treatment methods for hospitalized PAD
cases in Taiwan.
Some epidemiological studies of asymptomatic PAD in
Taiwan have been performed in specific disease groups.
The ABI was similarly used to detect PAD (ABI < 0.90).
For example, the records of 484 Taiwanese patients with
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had an overall prevalence of 18.2% and was significantly
more common in hemodialysis (HD) patients (21.8%) than
in peritoneal dialysis (PD) patients (4.8%) [25]. Another
prospective cross-sectional study showed that the preva-
lence of asymptomatic PAD among COPD patients in
Taiwan is lower (2.5% in the younger participants
(<65 years of age, n = 118) and 10% in the elderly par-
ticipants (≥65 years of age, n = 309)) than in Western
countries [26]. For the general Taiwanese population, a
recent survey enrolling ambulatory participants without
symptoms of PAD revealed that the overall prevalence
of asymptomatic PAD was 5.4% (2.8% in the younger
participants [<65 years of age, n = 1021] and 8.4% in the
elderly participants [≥65 years of age, n = 894]) [27].
The present study showed an invasive treatment inci-
dence of LE PAD in Taiwan and the latest cumulative
incidence of 7.48 per 10,000 in general population was
estimated in 2011. Age and period effects had been noted.
Otherwise, a gender difference was also observed, and the
incidence ratio (IR) of male vs female increased from 1.34
(in 2000) to 1.57 (in 2011). A significant increase in the
PAD prevalence with age has also been noted in American
adults, the PAD prevalence being 12.2% (95% confidence
interval (CI) = 10.9-13.5%); 7.0% (95% CI = 5.6-8.4%) for
those aged 60 to 69; and 12.5% (95% CI = 10.4-14.6%)
and 23.2% (95% CI = 19.8-26.7%) for those aged 70 to 79
and 80 and older [28].
The economic burden of PAD is high. Among the US
Medicare population, Medicare program outlays totaled
$3.87 billion for PAD and 88% of expenditures were
for inpatient care. In total, 6.8% of the elderly Medi-
care population received treatment for PAD. Treatment
increased with age, with rates of 4.5%, 7.5%, and 11.8% for
individuals aged 65–74, 75–84, and >85 years, respectively
[29]. In the present study, the national total medical ex-
penditure for these invasively-treated PAD cases was
found to have increased quickly, from $US 15.5 million
per year (in 2000) to $US 59.6 million per year (in
2011). Besides, the hospitalization incidence of PAD
was found to be at least 20 times higher in the elderly
(65 years or greater) than in the young (<50 years). This
indicated an increased medical burden of LE PAD, and
much more care for aged people should be instigated
by the health policy authority in Taiwan. A study based
on the REduction of Atherothrombosis for Continued
Health (REACH) Registry to estimate the 2-year associ-
ated costs in US patients with established PAD showed
that the mean cumulative hospitalization costs per
patient were $7,445, $7,000, $10,430, and $11,693 for
patients with asymptomatic PAD, a history of claudi-
cation, lower-limb amputation, and revascularization,
respectively (p = 0.007) [30]. In Taiwan, the present study
showed that the total direct medical cost of onehospitalized and invasively-treated PAD case ranged
from $US 4,600 to $US 5,900 on average, which is much
lower than other countries.
There is now a trend towards endovascular revascu-
larization for most PAD patients. A study using the US
Nationwide Inpatient Sample (NIS) database (1999–2007),
identifying patients who had an identifiable ICD-9 diag-
nosis code of atherosclerotic disease (claudication [440.21]
or limb threat [440.22-440.24]), showed that the number
of patients per year undergoing PTA increased threefold
[31]. Much more dramatically in Taiwan, the present
study revealed that the number of PTA procedures re-
markably increased by 15 times from 2000 to 2011,
which perhaps was partially contributed to by the dou-
bled numbers of hospitals with the ability to perform
PTA skills from 2000 to 2011. Data of US Medicare
beneficiaries analyzed between 1996 and 2006 revealed
that bypass surgery decreased by 42% (219 to 126 per
100,000; RR = 0.58; 95% CI: 0.5-0.7) [32]. In Taiwan, the
incidence of bypass surgery for PAD cases among resi-
dents aged 30 years or more was estimated as 8.4 per
100,000 and reduced to 6.4 per 100,000 from 2000 to
2011 in the present study, which showed a similar de-
creasing trend but was much lower than the study men-
tioned above. The deployment of medical resources for
vascular surgeries in Taiwan may be further evaluated
by the health policy authority.
Traditionally, amputation represents end-stage failure
for those with LE PAD. Using data from the US Centers
for Medicare & Medicaid Services (CMS) from 2000 to
2008, among 2,730,742 older patients (aged 65 years or
more) with identified PAD, the overall rate of LE ampu-
tation decreased from 7,258 per 100,000 patients with
PAD to 5,790 per 100,000 (p < 0.001 for trend) [33]. In
the present study, the number of limb amputations var-
ied annually, and ranged between 4,100 and 5,100 per
year (equal to 34 to 40 per 100,000) for the general
population. Compared to the above study in the US, the
amputation rate for LE PAD patients in Taiwan was
lower. Another study using the US Nationwide Inpatient
Sample (NIS) database (1999–2007) revealed that in-
hospital amputation rates were significantly higher for
patients who had PTA (7%) than a peripheral bypass graft
(BPG) (3.9%, odds ratio [OR], 1.67 [1.49-1.85]; p < 0.01)
or patients who underwent aorto-femoral bypass (ABF)
(3.0%; OR, 2.32 [1.79, 3.03]; p < 0.01) [31]. In our
present study, we calculated the 2-year failure rate of
PTAs, and found these to be 22.13%, 11.91% and 10.61%
(including 14.86%, 8.16% and 8.51% referred for am-
putation) among the first (2000–2001), second (2004–
2005) and third (2008–2009) cohorts, respectively.
Otherwise, aging, the female gender and higher co-
morbidities were found to be associated with the above
2-year PTA failure rates.
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tation rates of LE PAD. Data from the US Nationwide
Inpatient Sample (NIS) from 1998 to 2002 showed that
multivariate analysis indicated significantly higher odds
of amputation associated with the following variables:
nonwhites (1.91, 95% confidence interval [CI], 1.65,
2.20), low-income bracket (1.41, 95% CI, 1.18, 1.60), and
Medicare & Medicaid patients (1.81, 95% CI, 1.66, 1.97)
[34]. Another study of NIS data comparing two periods
(2001–2003 and 2004–2007) found that annually, the
total number of interventions increased by 15% and the
average annual number of endovascular interventions
increased by 78% (p < 0.001). After adjusting for age and
co-morbidities, African Americans were found to have a
2.4 times greater odds of amputation as compared with
Caucasians, whereas those under Medicare or Medicaid
had a 1.5 times greater odds [35]. These economically
disadvantaged patients were thought to have had a de-
layed diagnosis of peripheral vascular disease, probably
due to lack of adequate primary care or access to vascu-
lar interventions, or both. In Taiwan, the policy of list-
ing NHI-defined catastrophic illnesses exempts some
vulnerable populations from the co-payment economic
burden and protects their human rights with regards to
access to necessary medical care. A recent study re-
vealed that the prevalence of certificated catastrophic
illness in Taiwan’s elderly population utilizing ambula-
tory medical services was 10.16%. On average, 61.62
emergency department (ED) visits/1,000 persons (95% CI:
59.22–64.01) per month was estimated for elderly Taiwanese
with a catastrophic illness, which was significantly greater
than that for the elderly without a catastrophic illness (mean
33.53, 95% CI: 32.34–34.71). A significantly greater total
medical expenditure for emergency care was observed in
the catastrophic illness subgroup ($US 145.6 ± 193.5) as
compared with the non-catastrophic illness group ($US
108.7 ± 338.0) (p < 0.001) [13]. In the present study, these
disadvantaged populations, including low-income people
and catastrophic illness certificated patients, were evalu-
ated. Among 51.3% of all the enrolled PAD cases treated
with limb amputations, low-income people had a ten-
dency to undergo amputation due to their condition (OR:
1.41, 95% CI: 1.30-1.53); 37.6% of those treated with PTAs
with CIR had a greater opportunity to receive a PTA pro-
cedure (OR: 1.81, 95% CI: 1.76-1.87). Perhaps there was a
higher opportunity to receive amputation for those on a
low income, and a negative effect of low-income status on
the failure of original PTAs could be observed.
Conclusions
In Taiwan, a gender difference and age and period ef-
fects on the invasively-treated incidence of LE PAD were
observed, and the total direct medical cost of one hospi-
talized and invasively-treated PAD case was relativelycheap. Female, young and middle-aged people (30–50
and 50–65 years of age), DM patients and those on a
low income had a tendency to undergo amputation due
to PAD. The number of PTA procedures remarkably in-
creased, partially contributed to by the number of hospi-
tals performing PTAs having doubled, and the 2-year
failure rate of PTAs reduced from 2000 to 2011.
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